|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:AstraZeneca
gptkb:Elan_Drug_Technologies
gptkb:Takeda_Pharmaceutical_Company
gptkb:Acorda_Therapeutics
gptkb:Bristol-Myers_Squibb
gptkb:Neurocrine_Biosciences
gptkb:Wyeth
gptkb:Warner-Lambert
gptkb:Valeant_Pharmaceuticals
gptkb:Merck_&_Co.
gptkb:UCB_S.A.
Sanofi
Zymogenetics
|
|
gptkbp:CEO
|
gptkb:Kelly_Martin
|
|
gptkbp:discontinued
|
2014
|
|
gptkbp:employees
|
1,000 (2012)
|
|
gptkbp:founded
|
1969
|
|
gptkbp:founder
|
gptkb:Robert_A._Ingram
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
gptkb:Cambridge,_Massachusetts
gptkb:Dublin,_Ireland
gptkb:Los_Angeles,_California
gptkb:Research_Triangle_Park,_North_Carolina
gptkb:San_Diego,_California
gptkb:Seattle,_Washington
gptkb:Philadelphia,_Pennsylvania
gptkb:Wilmington,_Delaware
gptkb:South_San_Francisco,_California
New_York_City,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Elan Pharmaceuticals, Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:keyPeople
|
gptkb:David_E._Stout
gptkb:Kelly_Martin
|
|
gptkbp:partnerships
|
gptkb:Johnson_&_Johnson
gptkb:Pfizer
|
|
gptkbp:products
|
Alzheimer's disease treatments
Multiple sclerosis treatments
|
|
gptkbp:researchFocus
|
Immunology
Oncology
Neurology
|
|
gptkbp:revenue
|
$1.2 billion (2012)
|
|
gptkbp:services
|
Drug development
Drug delivery systems
|
|
gptkbp:stockSymbol
|
ELN
|
|
gptkbp:subsidiary
|
gptkb:Elan_Drug_Technologies
|
|
gptkbp:website
|
www.elan.com
|